Indication

Extensive-stage small cell lung cancer

Extensive-stage small cell lung cancer is an advanced, highly aggressive malignancy of neuroendocrine origin affecting the respiratory system, strongly associated with tobacco exposure. Read more about Extensive-stage small cell lung cancer

2 drugs 2 manufacturers

Drugs that treat it

Common Extensive-stage small cell lung cancer therapies.

Showing 1–2 of 2 drugs

Sort

IMFINZI (durvalumab)

ANTINEOPLASTIC - ANTI-PROGRAMMED DEATH-(PD-1/L1) MC ANTIBODY·BILIARY TRACT MALIGNANCY·+10

AstraZeneca Pharmaceuticals

IMDELLTRA (tarlatamab-dlle)

ANTINEOPLASTIC - IMMUNOTHERAPY, T-CELL ENGAGER·EXTENSIVE-STAGE SMALL CELL LUNG CANCER

AMGEN

Filter & compare in the drug finder →Opens the drug finder with Extensive-stage small cell lung cancer preselected.

News & literature

Coming soon

Related codes

Coming soon

About Extensive-stage small cell lung cancer.

Extensive-stage small cell lung cancer is an advanced, highly aggressive malignancy of neuroendocrine origin affecting the respiratory system, strongly associated with tobacco exposure.

It is clinically defined as cancer that has spread beyond a single hemithorax and ipsilateral regional lymph nodes—or cannot be encompassed within a tolerable single radiation field—commonly involving contralateral thoracic structures, malignant pleural or pericardial effusions, or distant hematogenous metastases to organs such as the liver, brain, bone, and adrenal glands.

Pathophysiologically characterized by rapid cellular proliferation, genomic instability, and widespread early dissemination, it accounts for approximately two-thirds of initial small cell lung cancer diagnoses and carries a poor long-term prognosis.

nih.gov
Extensive-stage small cell lung cancer is an advanced, highly aggressive malignancy of neuroendocrine origin affecting the respiratory system, strongly associated with tobacco exposure
lungevity.org
Extensive-stage small cell lung cancer is an advanced, highly aggressive malignancy of neuroendocrine origin affecting the respiratory system, strongly associated with tobacco exposure
cancer.gov
It is clinically defined as cancer that has spread beyond a single hemithorax and ipsilateral regional lymph nodes—or cannot be encompassed within a tolerable single radiation field—commonly involving contralateral thoracic structures, malignant pleural or pericardial effusions, or distant hematogenous metastases to organs such as the liver, brain, bone, and adrenal glands
nih.gov
It is clinically defined as cancer that has spread beyond a single hemithorax and ipsilateral regional lymph nodes—or cannot be encompassed within a tolerable single radiation field—commonly involving contralateral thoracic structures, malignant pleural or pericardial effusions, or distant hematogenous metastases to organs such as the liver, brain, bone, and adrenal glands
healthline.com
It is clinically defined as cancer that has spread beyond a single hemithorax and ipsilateral regional lymph nodes—or cannot be encompassed within a tolerable single radiation field—commonly involving contralateral thoracic structures, malignant pleural or pericardial effusions, or distant hematogenous metastases to organs such as the liver, brain, bone, and adrenal glands
cancer.org
It is clinically defined as cancer that has spread beyond a single hemithorax and ipsilateral regional lymph nodes—or cannot be encompassed within a tolerable single radiation field—commonly involving contralateral thoracic structures, malignant pleural or pericardial effusions, or distant hematogenous metastases to organs such as the liver, brain, bone, and adrenal glands Pathophysiologically characterized by rapid cellular proliferation, genomic instability, and widespread early dissemination,...
nih.gov
Pathophysiologically characterized by rapid cellular proliferation, genomic instability, and widespread early dissemination, it accounts for approximately two-thirds of initial small cell lung cancer diagnoses and carries a poor long-term prognosis
nih.gov
Pathophysiologically characterized by rapid cellular proliferation, genomic instability, and widespread early dissemination, it accounts for approximately two-thirds of initial small cell lung cancer diagnoses and carries a poor long-term prognosis
medicalnewstoday.com
Pathophysiologically characterized by rapid cellular proliferation, genomic instability, and widespread early dissemination, it accounts for approximately two-thirds of initial small cell lung cancer diagnoses and carries a poor long-term prognosis

Personalize your experience

Follow Extensive-stage small cell lung cancer and get updates as they land.

Create a free account

Already a member? Sign in

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it